

Northumbria Research Link

Citation: Wightman, Emma (2017) Potential benefits of phytochemicals against Alzheimer's disease. *Proceedings of the Nutrition Society*, 76 (2). pp. 106-112. ISSN 0029-6651

Published by: Cambridge University Press

URL: <http://dx.doi.org/10.1017/S0029665116002962>
<<http://dx.doi.org/10.1017/S0029665116002962>>

This version was downloaded from Northumbria Research Link:
<http://nrl.northumbria.ac.uk/id/eprint/29802/>

Northumbria University has developed Northumbria Research Link (NRL) to enable users to access the University's research output. Copyright © and moral rights for items on NRL are retained by the individual author(s) and/or other copyright owners. Single copies of full items can be reproduced, displayed or performed, and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata page. The content must not be changed in any way. Full items must not be sold commercially in any format or medium without formal permission of the copyright holder. The full policy is available online: <http://nrl.northumbria.ac.uk/policies.html>

This document may differ from the final, published version of the research and has been made available online in accordance with publisher policies. To read and/or cite from the published version of the research, please visit the publisher's website (a subscription may be required.)



**Northumbria
University**
NEWCASTLE



UniversityLibrary

Proceedings of the Nutrition Society



CAMBRIDGE
UNIVERSITY PRESS

Potential benefits of phytochemicals against Alzheimer's disease

Journal:	<i>Proceedings of the Nutrition Society</i>
Manuscript ID	Draft
Manuscript Type:	Scottish Meeting 2016
Date Submitted by the Author:	n/a
Complete List of Authors:	Wightman, Emma; Northumbria University, Psychology
Keywords:	Alzheimer's disease, Phytochemicals, Alkaloid, Terpene, Phenolic

SCHOLARONE™
Manuscripts

1 **Potential benefits of phytochemicals against Alzheimer’s disease**

2

3 Emma L. Wightman

4 Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle upon
5 Tyne, United Kingdom, NE1 8ST

6

7 **For correspondence and reprints:**

8 Emma L. Wightman

9 Brain, Performance and Nutrition Research Centre

10 Northumbria University

11 Newcastle, UK

12 NE1 8ST

13 Tel: (+44) 0191 2437253

14 Email: emma.l.wightman@northumbria.ac.uk

15

16 **Running title:** Phytochemicals and Alzheimer’s disease

17 **Keywords:** Alzheimer’s disease, phytochemicals, Alkaloid, Terpene, Phenolic

18

19

20

21

22

23

24

25

Abstract

Our current therapeutic drugs for Alzheimer's disease (AD) are predominantly derived from the alkaloid class of plant phytochemicals. These drugs, such as Galantamine and Rivastigmine, attenuate the decline in the cholinergic system but, as the alkaloids occupy the most dangerous end of the phytochemical spectrum (indeed they function as feeding deterrents and poisons to other organisms within the plant itself), they are often associated with unpleasant side effects. In addition, these cholinesterase inhibiting alkaloids target only 1 system in a disorder which is typified by multifactorial deficits. The more benign terpene (such as Ginkgo biloba, Ginseng, Melissa Officinalis (Lemon balm) and Salvia lavandulaefolia (sage)) and phenolic (such as Resveratrol) phytochemicals arguably offer a safer alternative and, as well as demonstrating efficacy in cholinesterase inhibition, these phytochemicals are able to target other salient systems; such as cerebral blood flow, free radical scavenging, anti-inflammation, inhibition of amyloid- β neurotoxicity, glucoregulation and interaction with other neurotransmitters (such as GABA) and signalling pathways (e.g. via kinase enzymes).

51 1. Background

52 The Brain Performance and Nutrition Research Centre (BPNRC) has, over the past decade or
53 so, investigated the cognitive and physical effects of over 20 essential nutrients and plant
54 secondary metabolites (phytochemicals) in healthy adults and children. The premise
55 underlying this body of research is that the supplementation of these compounds will, via a
56 multitude of mechanisms, enhance some aspect/s of cognitive function, mood and/or physical
57 performance. Naturally these studies produce varied results with some robust results evinced
58 from compounds such as caffeine⁽¹⁾, the neural substrates oxygen^(2; 3) and glucose⁽⁴⁾ and, more
59 recently, supplementation of the water soluble vitamins⁽⁵⁾. However, other supplemented
60 compounds appear almost to elicit no cognitive benefit to the young, healthy cohorts utilized;
61 the polyphenol resveratrol, for example^(6; 7; 8). This has led to the conclusion that some
62 supplements may have limited cognitive benefit in those who are within the cognitive peak
63 age-range (i.e. 18-35yrs)⁽⁹⁾ and that the mechanism underpinning their purported activity
64 might be of more interest and benefit to those who are experiencing natural and pathological
65 neurocognitive decline. Currently, pharmacological treatment options for pathological
66 neurocognitive disorders like Alzheimer’s disease (AD) are derived from the alkaloid class of
67 plant phytochemical compounds and this report will outline the disadvantages of this group
68 and present an argument for, instead, looking at the potential benefit that taking these drugs
69 from the more benign terpene and phenolic class of phytochemicals could provide in terms of
70 safety and clinical benefit.

71

72 2. Alzheimer’s disease and current treatment options from the alkaloid secondary
73 metabolites

74 AD is the most common form of dementia; a global, progressive neurocognitive disorder
75 typified by amyloid- β protein plaques outside of; and tau protein tangles inside of, neural cell

bodies which ultimately disrupts all cognitive processes and results in death⁽¹⁰⁾. The World Alzheimer Report 2015⁽¹¹⁾ estimates that, worldwide, 46.8 million people live with a dementia and that this number will double every 20 years. The main risk factor for developing AD, and other dementias, is age but this is a multifactorial disease which is also influenced (positively and negatively) by genetics (specifically the APOE gene has received much recent attention)⁽¹²⁾, diet⁽¹³⁾, nicotine^(14; 15) and alcohol⁽¹⁶⁾ consumption, free radical damage⁽¹⁷⁾, glucose regulation⁽¹⁸⁾, cerebral blood flow⁽¹⁹⁾, inflammation⁽²⁰⁾, ferrous metals⁽²¹⁾, hormones⁽²²⁾, socioeconomic status⁽²³⁾ and many more known and unknown variables.

The morphological changes to neurons that the above risk factors mediate are seen to predominantly disrupt the cholinergic neurotransmitter system and, in turn, the cognitive processes that the ubiquitous neurotransmitter acetylcholine sub-serves. Hence the progressive, global deficits in cognitive function seen in AD and the rationale for the target of current pharmaceutical drugs in attenuating this cholinergic decline⁽²⁴⁾. These drugs include Galantamine and Rivastigmine and, as a group of drugs defined as cholinesterase inhibitors (preventing the deamination of acetylcholine), these are currently the only approved first line pharmacologic treatment for AD in the UK⁽²⁵⁾. A recent Cochrane review reported that these drugs attenuate the decline in cognition, daily living and behaviour in AD when compared to placebo⁽²⁶⁾ but, interestingly, highlighted that none of the treatment effects were large. Cholinesterase drugs also lack efficacy in some stages of AD and here use of the antipsychotic drug Risperidone is often turned to in order to mediate challenging behaviour⁽²⁷⁾. Cholinesterase drugs are also associated with some quite unpleasant side effects (including gastrointestinal problems⁽²⁶⁾) and this is likely related to their current derivation from the alkaloid spectrum of plant secondary metabolites (hereafter referred to as phytochemicals).

100 Phytochemicals exist to mediate communication and protection of the static plant and, in
101 doing so, increase its survivability⁽²⁸⁾. These compounds fall into 1 of 3 categories; the
102 alkaloids, terpenes and phenolics, with this order denoting their potency from dangerous to
103 relatively benign, and each category appears to have a particular function. Here the alkaloids
104 are broadly expressed to deter the encroachment of other plants and potentially destructive
105 insects. The terpenes also play a role in defence and deterrence but their provision of
106 attractive colours and smells within the plant also demonstrates their role in attraction to
107 facilitate pollination. Finally, the phenolics occupy the most benign ground in terms of safety
108 and their role appears to be one of protection; expressed as they are when the plant comes
109 under some kind of stress⁽²⁸⁾. Of interest here, many phenolic and terpene phytochemicals
110 have also demonstrated efficacy against cholinergic decline and, beyond this, many of the
111 other factors contributing to AD; which the current alkaloid-based drugs do not. Added to
112 this, their relatively benign ecological roles means that they may also represent a safer way of
113 attenuating neurocognitive decline in AD. The following discusses those terpenes and
114 phenolics which represent the current most promising phytochemicals in this regard.

115

116 3. The potential benefit of terpene phytochemicals against Alzheimer’s disease

117 Terpenes are a diverse group of more than 30,000 lipid-soluble compounds and exhibit a
118 range of toxicity from deadly to entirely edible. This is in keeping with their broad range of
119 ecological roles which include antimicrobial properties and a range of measures which attract
120 symbiotes for the purposes of pollination, seed dispersal, and secondary protective roles. This
121 complex communication with insects requires the ability to interact directly with the central
122 nervous system (CNS) including hormones and the GABA and cholinergic neurotransmitter
123 systems; interactions which should also translate to the human CNS and, as a result, provide
124 benefit to AD^(28 for review).

125

126 3.1 Ginkgo biloba

127 Extracts of Ginkgo biloba leaf contain a number of bioactive components which include
 128 diterpenes, ginkgolides A, B, C, J and M, the sesquiterpene bilobalide and a range of
 129 flavonoids. The synergistic effects of these phytochemicals results in interactions with a
 130 number of CNS systems which would be expected to attenuate neurocognitive decline. These
 131 include an upregulation of the vasorelaxatory neurotransmitter nitric oxide (NO) and a
 132 resulting increase in cerebral blood flow (CBF), a downregulation in the enzymatic
 133 deamination of monoaminergic neurotransmitters, free radical scavenging and
 134 neuroprotection which includes reduced amyloid- β neurotoxicity^(29; 30; 31). These interactions
 135 support the prescription of Ginkgo for millennia in traditional Eastern forms of medicine for
 136 disorders of old age; including AD⁽³²⁾ and the beneficial effects seen in modern controlled
 137 intervention trials.

138 In 2002 a Cochrane review concluded that “overall there is promising evidence of
 139 improvement in cognition and function associated with Ginkgo”⁽³³⁾ but, in 2009, this message
 140 had changed to one blighted by “inconsistent” and “unconvincing” results⁽³⁴⁾. This is despite
 141 a study conducted in the same year where cognitive decline, as assessed by the Alzheimer’s
 142 disease assessment scale (ADAS-Cog), was attenuated by Ginkgo⁽³⁵⁾ but perhaps represents
 143 the influence of several small, heterogeneous studies on a research area still in its infancy.
 144 Nevertheless, since this review, a handful of larger scale reviews have reported more
 145 promising results of Ginkgo. In 2010 a review of 9 studies, comprising 2372 patients with
 146 various dementias, found that ginkgo attenuated declines in cognitive performance across all
 147 dementia groups tested and additional improvements in activities of daily living were seen in
 148 the AD groups⁽³⁶⁾. In the same year a review of 6 studies found that 6 months administration
 149 of ginkgo resulted in significant improvements on the ADAS-cog⁽³⁷⁾. Importantly, this result

was evinced when baseline risk was taken into account and might represent an important methodological consideration in AD research. In support of this, a separate review⁽³⁸⁾ found that improvements seen in daily living, cognitive function and amelioration of neuropsychiatric symptoms (such as psychosis, agitation, aggression, anxiety, euphoria/dysphoria or disordered motor behaviour), in a review of 6 studies comprising 1800 participants with AD, were most striking in those suffering significant levels of neuropsychiatric symptoms; thus individual differences in risk levels and severity of symptoms likely has an impact on response to Ginkgo and overall study findings; especially if small cohorts are utilized in individual trials.

3.2 Ginseng

Ginseng has a 5000yr history of medicinal consumption⁽³⁹⁾ and comprises 40 or more bioactive saponins (known as ginsenosides) which exert anti-fungal/viral/bacterial/feeding effects within the plant^(40; 41). Again, this terpene-derived nutritional supplement demonstrates efficacy in interacting with numerous physiological systems, including acting as an antioxidant, stimulating NO production and acting as a ligand for glucocorticoid and androgen receptors; interactions which, among others, are seen to increase immune function, enhance CNS function and prevent cardiovascular and other diseases in animal models⁽⁴²⁾. Specific neurocognitive interactions with neurotransmitter function and the processes of neurogenesis and long-term potentiation are also observed to exert anti-stress, antidepressant, and anxiolytic effects, to moderate fatigue and improve memory in impaired rodents^(43; 44).

Research in young healthy participants is still in its infancy and buoyed by heterogeneous methodology but, on the whole, provides promise in terms of cognitive enhancement^(45; 46; 47; 48). *In vitro* and animal data supports the potential for ginseng to be of specific benefit to AD-induced cognitive decline where ginsenosides have been observed to minimise the inhibitory

effect of amyloid- β protein on cholinergic transmission⁽⁴⁹⁾ and, in turn, prevent the resulting amnesiac effects in rats⁽⁵⁰⁾. To the best of current knowledge, however, only 2 trials exist which investigate whether these cognitive benefits also extend to AD in humans. The first of these reports on the 12 week consumption of 9g/day Korean ginseng in 15 patients with dementia where scores on the ADAS and clinical dementia rating (CDR) were significantly improved⁽⁵¹⁾. The second trial is a follow-up of patients in this same trial after 24 weeks where a significant improvement on the Korean Mini Mental State Exam (MMSE) was evinced following 4.5- and 9g/day ginseng and maintained at 48 and 96 weeks⁽⁵²⁾.

3.3 Melissa Officinalis (Lemon balm)

Melissa is another terpene with a centuries-long history for treating disorders which modern research has confirmed efficacy for; including as a memory and mood enhancer⁽⁵³⁾. The bioactives underpinning these effects include monoterpenes and sesquiterpenes; which include 1, 8 cineole⁽⁵⁴⁾, and the CNS-relevant effects of these compounds includes antioxidant activity^(55; 56), activation of the cholinergic system (including cholinesterase inhibition)^(55; 57; 58; 59) and upregulation of GABAergic neurons⁽⁶⁰⁾.

These interactions would suggest benefit to AD sufferers and, indeed, 1 of the only 2 controlled trials which has investigated Melissa here observed reduced agitation and improved cognitive (ADAS-cog) and behavioural function (as assessed by the Cognitive Drug Research (CDR) test battery) following 16 weeks administration of an alcoholic-Melissa tincture in a group of mild-moderate sufferers⁽⁶¹⁾. The other of the 2 studies, however, failed to find statistically significant differences in AD symptoms with Melissa⁽⁶²⁾. This study, though, administered Melissa in the form of an aromatherapy spray (dispersed once in the am and pm in patient rooms), or essential oil hand massage (with a 3rd group receiving a combination), which also contained lavender. This novel approach to

administration presents an unknown quantity in terms of subsequent plasma levels of Melissa and time needed for the bioactives to reach the CNS and, as such, makes it difficult to compare with the above study and related studies which administer phytochemicals orally. It could also be the case that the alcoholic matrix in the initial study in some way enhanced, or indeed was solely responsible for, the significant effects seen there. Nevertheless, it is important to note that the latter study did observe clinical benefit to some participants and this may indicate the very important role of individual differences in response to terpene phytochemicals; a consideration also noted with Ginkgo studies above. Here too it may be the case that pre-AD differences and current symptom severity influence the role that terpenes play and, with the Melissa essential oil study specifically, it could be that the response to scent (including lavender; which contains the active terpene linalool) and the pleasant sensation of being massaged, interact to produce effects which are of benefit to some and not others.

3.4 *Salvia Lavandulaefolia* and *Officinalis* (Sage)

Sage has a history stretching back as far as the ancient Greeks where it was used as a cognitive enhancer and to prevent age-related decline; hence the derivation of the word sage in relation to wisdom. The 2 most abundant bioactive monoterpenes in sage are 1, 8 cineole and camphor and, of interest here, these monoterpenes have demonstrated potent cholinesterase inhibiting properties^(63; 64; 65; 66); with 1, 8 cineole alone evincing the greatest effects⁽⁶³⁾. These CNS effects produce enhanced secondary memory, accuracy and attention in healthy aged (over 65yrs) participants⁽⁶⁷⁾ and consumption of this terpene, in the form of an essential oil, is reportedly well tolerated in a small group (N=11) of patients aged 76-95yrs with mild-moderate AD following 6 weeks of 50-150µl daily consumption of *salvia officinalis* (SO)⁽⁶⁸⁾. The latter study didn't observe any statistically significant cognitive

benefit but this was not the *a priori* aim of the study and this is reflected in the sample size. Nevertheless the authors do report ‘positive indications’ on the cognitive test battery used (CDR) and this is in line with the only other trial investigating the benefit of sage in AD⁽⁶⁹⁾. Here 19 participants (65-80yrs), with mild-moderate AD, consumed an SO-alcoholic tincture for 16 weeks and better outcomes on the ADAS-cog, compared to the placebo controls, was observed. This study also demonstrated a trend towards reduced agitation in the SO group.

4. The potential benefit of phenolic phytochemicals against Alzheimer’s disease

Currently ~10,000 compounds have been classified as polyphenols and this large class comprises both flavonoid and non-flavonoid forms. The former comprise the largest grouping and these can be further sub-divided into isoflavones (found in soy and soy products), flavones (found, for example, in sweet pepper), flavanones (found in citrus fruits), flavanols (which can be further sub-categorised into flavan-3-ols (found in tea) and proanthocyanidins (found in fruits)), flavonols (fruits and vegetables; specifically onions) and anthocyanins (specifically found in berries)⁽⁷⁰⁾.

Epidemiological data has established links between the consumption of polyphenol-rich diets, and specific polyphenols, and reduced incidences of AD in human populations. Consumption of fruits and vegetables and total levels of flavonoids are associated with protection against, or slowed progression of, AD and other dementias^(71; 72; 73). Large cohort studies have also evidenced links between neurocognitive protection (as indexed in all cases by scores on the MMSE) and tea consumption in elderly cohorts^(74; 75) as well as chocolate and red-wine⁽⁷⁶⁾.

4.1 Resveratrol

Resveratrol derives from a sub-class of non-flavonoid polyphenols termed stilbenes and is found in limited sources which include grapes and, as a result, wine. Resveratrol has received

250 much research attention regarding its potential to benefit a number of disease states;
251 including cardiovascular disease⁽⁷⁷⁾, cancer⁽⁷⁸⁾ and even life extension in a range of animal
252 models⁽⁷⁹⁾. The many and varied health effects attributed to resveratrol are likely underpinned
253 by the multifarious biological targets that it interacts with. These include, but are not limited
254 to, cyclooxygenase (COX) 1 and 2; hence the anti-inflammatory effects of resveratrol,
255 sirtuins and various kinases; enabling resveratrol to interact directly with cell signalling and
256 DNA/RNA and lipoproteins; explaining resveratrols link to cardiovascular health⁽⁸⁰⁾.
257 Interaction with these targets, and others like upregulation of CBF^(6; 7), and the ability of
258 resveratrol to attenuate amyloid- β induced cell death *in vitro*⁽⁸¹⁾, suggests that this polyphenol
259 should be capable of beneficial therapeutic potential in AD. Indeed, results from animal
260 models supports the function of resveratrol here with reduced markers of pathology, e.g.
261 amyloid- β plaques⁽⁸²⁾, and behavioural deficits, e.g. improved learning and memory⁽⁸³⁾, in
262 response to resveratrol exposure and consumption (25mg/kg/day) of resveratrol respectively.

263 However, to the best of current knowledge, only 1 study exists which investigates resveratrol
264 in human volunteers with AD. Here a phase-2 randomized, placebo-controlled, double-blind
265 12 month trial of 500mg/day (escalating to 1000mg x2 daily) resveratrol was conducted in
266 participants with mild-moderate AD⁽⁸⁴⁾. Unfortunately the therapeutic measures of this study
267 were limited and, whilst amyloid- β markers were reduced by resveratrol, this was not more
268 significant than in the placebo group, and brain volume loss was not attenuated. Resveratrol
269 consumption was generally well tolerated but participants did report significant
270 gastrointestinal problems and weight loss which is likely due to the high dose being received
271 after escalation as these side effects aren't seen often in the literature with doses at or lower
272 than 500mg.

273

274 **Conclusions**

This review began with the assertion that our current alkaloid-derived AD pharmaceutical treatments, like Galantamine and Rivastigmine, produce unpleasant side effects and, ultimately, target only 1 of the multifactorial deficits of this progressive neurocognitive disorder. Whilst this sole target of attenuating cholinergic decline is arguably one, if not the, most important and easily influenced today, it was argued here that the terpene and phenolic groupings of plant phytochemicals might offer an equally efficacious and safer alternative for AD drugs which target multiple deficits. The terpene and phenolic studies presented here are few and a clear, overall view hindered by heterogeneous trials where sample size, method of assessment, trial length, route of administration and individual differences associated with pre-AD status and current severity of symptoms vary or are not considered. Another area which future studies should focus, and something which resonated from several talks at the Nutrition Society spring conference, is the concept of ‘responders’ and ‘non-responders’ in phytochemical research. These terms refer to individuals who experience an anticipated pharmacokinetic response to consumption of drugs, and those who don’t, respectively; with this journey based on a whole host of known and unknown factors. This likely includes the speed of gut transit, the microbiotic profile of the gastrointestinal tract and the functionality of efflux pumps and these factors will be unique to each participant. It’s likely that the impact of these individual differences will be diluted in large cohorts but, apart from the meta-analyses discussed, one common factor across terpene and phenolic research trials is relatively small sample sizes. Studies with these phytochemicals undoubtedly hold promise but robust and replicable outcomes won’t be evinced until the above methodological constraints are addressed.

Acknowledgements

I would like to thank Professor David Kennedy for his help in preparing the Nutrition Society
spring conference presentation of the same title and, therefore, this manuscript.

Financial support

This research received no specific grant from any funding agency, commercial or not-for-
profit sectors.

Conflict of interest

None

324

References

- 325 1. Haskell CF, Kennedy DO, Wesnes KA *et al.* (2005) Cognitive and mood improvements of caffeine in
326 habitual consumers and habitual non-consumers of caffeine. *Psychopharmacology* **179**, 813-825.
- 327 2. Moss MC, Scholey AB, Wesnes K (1998) Oxygen administration selectively enhances cognitive
328 performance in healthy young adults: a placebo-controlled double-blind crossover study.
329 *Psychopharmacology (Berl)* **138**, 27-33.
- 330 3. Scholey A, Moss M, Neave N *et al.* (1999) Cognitive performance, hyperoxia, and heart rate
331 following oxygen administration in healthy young adults. *Physiology & behavior* **67**, 783-789.
- 332 4. Scholey A, Laing S, Kennedy D (2006) Blood glucose changes and memory: Effects of manipulating
333 emotionality and mental effort. *Biological Psychology* **71**, 12-19.
- 334 5. Kennedy DO, Stevenson EJ, Jackson PA *et al.* (2016) Multivitamins and minerals modulate whole-
335 body energy metabolism and cerebral blood-flow during cognitive task performance: a double-blind,
336 randomised, placebo-controlled trial. *Nutrition & metabolism* **13**, 1.
- 337 6. Kennedy DO, Wightman EL, Reay JL *et al.* (2010) Effects of resveratrol on cerebral blood flow
338 variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover
339 investigation. *Am J Clin Nutr* **91**, 1590-1597.
- 340 7. Wightman E, Reay J, Haskell C *et al.* (2014) Effects of resveratrol alone or in combination with
341 piperine on cerebral blood flow parameters and cognitive performance in humans: a randomised,
342 double-blind, placebo-controlled, crossover investigation. *British Journal of Nutrition* **112**, 203-213.
- 343 8. Wightman EL, Haskell-Ramsay CF, Reay JL *et al.* (2015) The effects of chronic trans-resveratrol
344 supplementation on aspects of cognitive function, mood, sleep, health and cerebral blood flow in
345 healthy, young humans. *British Journal of Nutrition* **114**, 1427-1437.
- 346 9. Rönnlund M, Nyberg L, Bäckman L *et al.* (2005) Stability, growth, and decline in adult life span
347 development of declarative memory: Cross-sectional and longitudinal data from a population-based
348 study. *Psychology and aging* **20**, 3-18.
- 349 10. Association As (2016) 2016 Alzheimer's disease facts and figures. *Alzheimer's & Dementia* **12**,
350 459-509.
- 351 11. International AsD (2015) *World Alzheimer report 2015: The global impact of dementia. An*
352 *analysis of prevalence, incidence, cost and trends.*
- 353 12. Karch CM, Goate AM (2015) Alzheimer's disease risk genes and mechanisms of disease
354 pathogenesis. *Biological psychiatry* **77**, 43-51.
- 355 13. Luchsinger JA, Mayeux R (2004) Dietary factors and Alzheimer's disease. *The Lancet Neurology* **3**,
356 579-587.
- 357 14. Lee P (1994) Smoking and Alzheimer's disease: a review of the epidemiological evidence.
358 *Neuroepidemiology* **13**, 131-144.
- 359 15. Durazzo TC, Mattsson N, Weiner MW *et al.* (2014) Smoking and increased Alzheimer's disease
360 risk: a review of potential mechanisms. *Alzheimer's & Dementia* **10**, S122-S145.
- 361 16. Mukamal KJ, Kuller LH, Fitzpatrick AL *et al.* (2003) Prospective study of alcohol consumption and
362 risk of dementia in older adults. *Jama* **289**, 1405-1413.
- 363 17. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. *Free Radical Biology*
364 *and Medicine* **23**, 134-147.
- 365 18. Vignini A, Giulietti A, Nanetti L *et al.* (2013) Alzheimer's disease and diabetes: new insights and
366 unifying therapies. *Current diabetes reviews* **9**, 218-227.
- 367 19. Kalaria RN (2000) The role of cerebral ischemia in Alzheimer's disease. *Neurobiology of aging* **21**,
368 321-330.
- 369 20. Matrone C, Djelloul M, Taglialatela G *et al.* (2015) Inflammatory risk factors and pathologies
370 promoting Alzheimer's disease progression: is RAGE the key. *Histology and histopathology* **30**, 125-
371 139.
- 372 21. Adlard PA, Bush AI (2006) Metals and Alzheimer's disease. *Journal of Alzheimer's Disease* **10**, 145-
373 163.

- 374 22. Vest RS, Pike CJ (2013) Gender, sex steroid hormones, and Alzheimer's disease. *Horm Behav* **63**,
375 301-307.
- 376 23. Sattler C, Toro P, Schönknecht P *et al.* (2012) Cognitive activity, education and socioeconomic
377 status as preventive factors for mild cognitive impairment and Alzheimer's disease. *Psychiatry*
378 *research* **196**, 90-95.
- 379 24. Mufson EJ, Counts SE, Perez SE *et al.* (2008) Cholinergic system during the progression of
380 Alzheimer's disease: therapeutic implications. *Expert review of neurotherapeutics* **8**, 1703-1718.
- 381 25. NICE (2009) *Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of*
382 *Alzheimer's disease*.: National Institute of Clinical Excellence, UK.
- 383 26. Birks J, Craig D (2013) *No consistent evidence of efficacy of galantamine in vascular cognitive*
384 *impairment*. *Health*. Cochrane library.
- 385 27. Society As (2016) Treating behavioural and psychological symptoms of dementia.
386 [https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=1191&pageNumber=](https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=1191&pageNumber=2)
387 [2](https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=1191&pageNumber=2) (accessed 24/05/16)
- 388 28. Kennedy DO, Wightman EL (2011) Herbal extracts and phytochemicals: plant secondary
389 metabolites and the enhancement of human brain function. *Advances in Nutrition: An International*
390 *Review Journal* **2**, 32-50.
- 391 29. Fehske CJ, Leuner K, Müller WE (2009) Ginkgo biloba extract (EGb761®) influences
392 monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic
393 treatment. *Pharmacological Research* **60**, 68-73.
- 394 30. Chan PC, Xia QS, Fu PP (2007) Ginkgo biloba leave extract: Biological, medicinal, and toxicological
395 effects. *Journal of Environmental Science and Health Part C-Environmental Carcinogenesis &*
396 *Ecotoxicology Reviews* **25**, 211-244.
- 397 31. DeFeudis FV, Drieu K (2004) "Stress-alleviating" and "vigilance-enhancing" actions of Ginkgo
398 biloba extract (EGb 761). *Drug Development Research* **62**, 1-25.
- 399 32. Berger P (2001) Ginkgo leaf extract. *Medical Herbalism* **2**, 5-6.
- 400 33. Birks J, Grimley Evans J (2002) Ginkgo biloba for cognitive impairment and dementia. *The*
401 *Cochrane Library*.
- 402 34. Birks J, Evans JG (2009) Ginkgo biloba for cognitive impairment and dementia. *Cochrane*
403 *Database of Systematic Reviews*, CD003120.
- 404 35. Snitz BE, O'Meara ES, Carlson MC *et al.* (2009) Ginkgo biloba for preventing cognitive decline in
405 older adults: a randomized trial. *Jama* **302**, 2663.
- 406 36. Weinmann S, Roll S, Schwarzbach C *et al.* (2010) Effects of Ginkgo biloba in dementia: systematic
407 review and meta-analysis. *BMC geriatrics* **10**, 1.
- 408 37. Wang B, Wang H, Song Y *et al.* (2010) Effectiveness of standardized ginkgo biloba extract on
409 cognitive symptoms of dementia with a six-month treatment: a bivariate random effect meta-
410 analysis. *Pharmacopsychiatry* **43**, 86-91.
- 411 38. Janßen IM, Sturtz S, Skipka G *et al.* (2010) Ginkgo biloba in Alzheimer's disease: a systematic
412 review. *Wiener Medizinische Wochenschrift* **160**, 539-546.
- 413 39. Yun TK (2001) Brief introduction of Panax ginseng CA Meyer. *Journal of Korean Medical Science*
414 **16**, 3-5.
- 415 40. Osbourn A (1996) Saponins and plant defence - A soap story. *Trends in Plant Science* **1**, 4-9.
- 416 41. Sparg SG, Light ME, van Staden J (2004) Biological activities and distribution of plant saponins.
417 *Journal of Ethnopharmacology* **94**, 219-243.
- 418 42. Lu JM, Yao QZ, Chen CY (2009) Ginseng Compounds: An Update on their Molecular Mechanisms
419 and Medical Applications. *Current Vascular Pharmacology* **7**, 293-302.
- 420 43. Attele AS, Wu JA, Yuan C-S (1999) Ginseng pharmacology: multiple constituents and multiple
421 actions. *Biochemical pharmacology* **58**, 1685-1693.
- 422 44. Dang HX, Chen Y, Liu XM *et al.* (2009) Antidepressant effects of ginseng total saponins in the
423 forced swimming test and chronic mild stress models of depression. *Progress in Neuro-*
424 *Psychopharmacology & Biological Psychiatry* **33**, 1417-1424.

- 425 45. Kennedy DO, Scholey AB, Wesnes KA (2001) Differential, dose dependent changes in cognitive
426 performance following acute administration of a Ginkgo biloba/Panax ginseng combination to
427 healthy young volunteers. *Nutritional Neuroscience* **4**, 399-412.
- 428 46. Kennedy DO, Scholey AB, Wesnes KA (2002) Modulation of cognition and mood following
429 administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to
430 healthy young adults. *Physiology & Behavior* **75**, 739-751.
- 431 47. Reay JL, Kennedy DO, Scholey AB (2005) Single doses of Panax ginseng (G115) reduce blood
432 glucose levels and improve cognitive performance during sustained mental activity. *Journal of*
433 *Psychopharmacology* **19**, 357-365.
- 434 48. Reay JL, Scholey AB, Kennedy DO (2010) Panax ginseng (G115) improves aspects of working
435 memory performance and subjective ratings of calmness in healthy young adults. *Human*
436 *Psychopharmacology-Clinical and Experimental* **25**, 462-471.
- 437 49. Lee T, Shiao Y-J, Chen C-F *et al.* (2001) Effect of ginseng saponins on b-amyloid-suppressed
438 acetylcholine release from rat hippocampal slices. *Planta Med* **67**, 634-637.
- 439 50. Wang LC, Wang B, Ng S-Y *et al.* (2006) Effects of ginseng saponins on β -amyloid-induced amnesia
440 in rats. *Journal of ethnopharmacology* **103**, 103-108.
- 441 51. Heo JH, Lee ST, Chu K *et al.* (2008) An open-label trial of Korean red ginseng as an adjuvant
442 treatment for cognitive impairment in patients with Alzheimer's disease. *Eur J Neurol* **15**, 865-868.
- 443 52. Heo J-H, Lee S-T, Oh M-J *et al.* (2011) Improvement of cognitive deficit in Alzheimer's disease
444 patients by long term treatment with Korean red ginseng. *Journal of ginseng research* **35**, 457-461.
- 445 53. Kennedy DO, Scholey AB (2006) The psychopharmacology of European herbs with cognition-
446 enhancing properties. *Current Pharmaceutical Design* **12**, 4613-4623.
- 447 54. Tittel G, Wagner H, Bos R (1982) CHEMICAL-COMPOSITION OF THE ESSENTIAL OIL FROM
448 MELISSA. *Planta Medica* **46**, 91-98.
- 449 55. Ferreira A, Proença C, Serralheiro M *et al.* (2006) The in vitro screening for acetylcholinesterase
450 inhibition and antioxidant activity of medicinal plants from Portugal. *Journal of ethnopharmacology*
451 **108**, 31-37.
- 452 56. Pereira RP, Fachinetto R, de Souza Prestes A *et al.* (2009) Antioxidant effects of different extracts
453 from Melissa officinalis, Matricaria recutita and Cymbopogon citratus. *Neurochemical Research* **34**,
454 973-983.
- 455 57. Perry N, Court G, Bidet N *et al.* (1996) European herbs with cholinergic activities: Potential in
456 dementia therapy. *International Journal of Geriatric Psychiatry* **11**, 1063-1069.
- 457 58. Wake G (2000) CNS acetylcholine receptor activity in European medicinal plants traditionally
458 used to improve failing memory. *Journal of ethnopharmacology* **69**, 105-114.
- 459 59. Dastmalchi K, Ollilainen V, Lackman P *et al.* (2009) Acetylcholinesterase inhibitory guided
460 fractionation of Melissa officinalis L. *Bioorganic & Medicinal Chemistry* **17**, 867-871.
- 461 60. Awad R, Muhammad A, Durst T *et al.* (2009) Bioassay-guided Fractionation of Lemon Balm
462 (Melissa officinalis L.) using an In Vitro Measure of GABA Transaminase Activity. *Phytotherapy*
463 *Research* **23**, 1075-1081.
- 464 61. Akhondzadeh S, Noroozian M, Mohammadi M *et al.* (2003) Melissa officinalis extract in the
465 treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised,
466 placebo controlled trial. *J Neurol Neurosurg Psychiatry* **74**, 863-866.
- 467 62. Ballard CG, O'Brien JT, Reichelt K *et al.* (2002) Aromatherapy as a safe and effective treatment for
468 the management of agitation in severe dementia: The results of a double-blind, placebo-controlled
469 trial with Melissa. *Journal of Clinical Psychiatry* **63**, 553-558.
- 470 63. Savelev S, Okello E, Perry NSL *et al.* (2003) Synergistic and antagonistic interactions of
471 anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. *Pharmacology Biochemistry and*
472 *Behavior* **75**, 661-668.
- 473 64. Savelev SU, Okello EJ, Perry EK (2004) Butyryl- and acetyl-cholinesterase inhibitory activities in
474 essential oils of Salvia species and their constituents. *Phytotherapy Research* **18**, 315-324.

- 475 65. Perry NS, Houghton PJ, Theobald A *et al.* (2000) In-vitro inhibition of human erythrocyte
476 acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. *The Journal of*
477 *pharmacy and pharmacology* **52**, 895-902.
- 478 66. Perry NSL, Houghton PJ, Jenner P *et al.* (2002) Salvia lavandulaefolia essential oil inhibits
479 cholinesterase in vivo. *Phytomedicine : international journal of phytotherapy and*
480 *phytopharmacology* **9**, 48-51.
- 481 67. Scholey A, Tildesley N, Ballard C *et al.* (2008) An extract of Salvia (sage) with anticholinesterase
482 properties improves memory and attention in healthy older volunteers. *Psychopharmacology* **198**,
483 127-139.
- 484 68. Perry NSL, Bollen C, Perry EK *et al.* (2003) Salvia for dementia therapy: review of pharmacological
485 activity and pilot tolerability clinical trial. *Pharmacology Biochemistry and Behavior* **75**, 651-659.
- 486 69. Akhondzadeh S, Noroozian M, Mohammadi M *et al.* (2003) Salvia officinalis extract in the
487 treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and
488 placebo-controlled trial. *Journal of Clinical Pharmacy and Therapeutics* **28**, 53-59.
- 489 70. Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. *The Journal of*
490 *nutrition* **130**, 2073S-2085S.
- 491 71. Barberger-Gateau P, Raffaitin C, Letenneur L *et al.* (2007) Dietary patterns and risk of dementia
492 The Three-City cohort study. *Neurology* **69**, 1921-1930.
- 493 72. Commenges D, Scotet V, Renaud S *et al.* (2000) Intake of flavonoids and risk of dementia.
494 *European journal of epidemiology* **16**, 357-363.
- 495 73. Letenneur L, Proust-Lima C, Le Gouge A *et al.* (2007) Flavonoid intake and cognitive decline over
496 a 10-year period. *American journal of epidemiology* **165**, 1364-1371.
- 497 74. Ng T, Feng L, Niti M *et al.* (2008) Tea consumption and cognitive impairment and decline in older
498 Chinese adults. *American Journal of Clinical Nutrition* **88**, 224-231.
- 499 75. Kuriyama S, Hozawa A, Ohmori K *et al.* (2006) Green tea consumption and cognitive function: a
500 cross-sectional study from the Tsurugaya Project 1. *The American journal of clinical nutrition* **83**, 355.
- 501 76. Nurk E, Refsum H, Drewnowski CA *et al.* (2009) Intake of flavonoid-rich wine, tea, and chocolate by
502 elderly men and women is associated with better cognitive test performance. *The Journal of*
503 *nutrition* **139**, 120-127.
- 504 77. Zordoky BN, Robertson IM, Dyck JR (2015) Preclinical and clinical evidence for the role of
505 resveratrol in the treatment of cardiovascular diseases. *Biochimica et Biophysica Acta (BBA)-*
506 *Molecular Basis of Disease* **1852**, 1155-1177.
- 507 78. Carter LG, D'Orazio JA, Pearson KJ (2014) Resveratrol and cancer: focus on in vivo evidence.
508 *Endocrine-related cancer* **21**, R209-R225.
- 509 79. Hector KL, Lagisz M, Nakagawa S (2012) The effect of resveratrol on longevity across species: a
510 meta-analysis. *Biology letters*, rsbl20120316.
- 511 80. Britton RG, Kooroor C, Brown K (2015) Direct molecular targets of resveratrol: identifying key
512 interactions to unlock complex mechanisms. *Annals of the New York Academy of Sciences* **1348**, 124-
513 133.
- 514 81. Han YS, Zheng WH, Bastianetto S *et al.* (2004) Neuroprotective effects of resveratrol against β -
515 amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. *British*
516 *journal of pharmacology* **141**, 997-1005.
- 517 82. Karuppagounder SS, Pinto JT, Xu H *et al.* (2009) Dietary supplementation with resveratrol
518 reduces plaque pathology in a transgenic model of Alzheimer's disease. *Neurochemistry*
519 *International* **54**, 111-118.
- 520 83. Ma X, Sun Z, Liu Y *et al.* (2013) Resveratrol improves cognition and reduces oxidative stress in
521 rats with vascular dementia. *Neural regeneration research* **8**, 2050.
- 522 84. Turner R, Thomas R, Craft S *et al.* (2015) Resveratrol is safe and well-tolerated in individuals with
523 mild-moderate dementia due to Alzheimer's disease.(S33. 009). *Neurology* **84**, S33. 009.
- 524